Literature DB >> 19099484

A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.

Nicholas J Vietri1, Bret K Purcell, Steven A Tobery, Suzanne L Rasmussen, Elizabeth K Leffel, Nancy A Twenhafel, Bruce E Ivins, Mark D Kellogg, Wendy M Webster, Mary E Wright, Arthur M Friedlander.   

Abstract

BACKGROUND: Postexposure prophylaxis of inhalational anthrax requires prolonged antibiotic therapy or antibiotics and vaccination. The duration of treatment for established anthrax is controversial, because retained spores may germinate and cause disease after antibiotics are discontinued. Using rhesus macaques, we determined whether a short course of antibiotic treatment, as opposed to prophylaxis, could effectively treat inhalational anthrax and prevent disease caused by the germination of spores after discontinuation of antibiotics.
METHODS: Two groups of 10 rhesus macaques were exposed to an aerosol dose of Bacillus anthracis spores. Animals in group 1 received ciprofloxacin prophylaxis beginning 1-2 h after exposure. Those in group 2 began receiving ciprofloxacin after becoming bacteremic, and treatment was continued for 10 days. When each group 2 animal completed 10 days of therapy, the prophylactic antibiotic was discontinued in the paired group 1 animal.
RESULTS: In group 1 (prophylaxis), no deaths occurred during antibiotic treatment, but only 2 (20%) of 10 animals survived after antibiotics were discontinued. In contrast, in group 2 (treatment), 3 deaths occurred during antibiotic treatment, but all 7 animals (100%) alive after 10 days of therapy survived when antibiotics were discontinued.
CONCLUSIONS: In the treatment of inhalational anthrax, the prolonged course of antibiotics required to achieve prophylaxis may not be necessary to prevent anthrax that results from the germination of retained spores after the discontinuation of antibiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19099484     DOI: 10.1086/596063

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Authors:  Boris Ionin; Robert J Hopkins; Brett Pleune; Gloria S Sivko; Frances M Reid; Kristin H Clement; Thomas L Rudge; Gregory V Stark; Alison Innes; Suha Sari; Tina Guina; Cris Howard; Jeffrey Smith; M Lisa Swoboda; Ekaterina Vert-Wong; Virginia Johnson; Gary S Nabors; Mario H Skiadopoulos
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

Review 2.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  Accurate and selective quantification of anthrax protective antigen in plasma by immunocapture and isotope dilution mass spectrometry.

Authors:  Maria I Solano; Adrian R Woolfitt; Anne E Boyer; Renato C Lins; Katie Isbell; Maribel Gallegos-Candela; Hercules Moura; Carrie L Pierce; John R Barr
Journal:  Analyst       Date:  2019-03-25       Impact factor: 4.616

4.  Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.

Authors:  G S Sivko; G V Stark; K P Tordoff; K L Taylor; E Glaze; M VanRaden; J M Schiffer; J A Hewitt; C P Quinn; E O Nuzum
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

5.  Antibiotics cure anthrax in animal models.

Authors:  Shay Weiss; David Kobiler; Haim Levy; Avi Pass; Yakir Ophir; Nili Rothschild; Arnon Tal; Josef Schlomovitz; Zeev Altboum
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

6.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

7.  Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.

Authors:  Nicholas J Vietri; Steven A Tobery; Donald J Chabot; Susham Ingavale; Brandon C Somerville; Jeremy A Miller; Chris W Schellhase; Nancy A Twenhafel; David P Fetterer; Christopher K Cote; Christopher P Klimko; Anne E Boyer; Adrian R Woolfitt; John R Barr; Mary E Wright; Arthur M Friedlander
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

8.  Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques.

Authors:  Anne E Boyer; Conrad P Quinn; Alex R Hoffmaster; Thomas R Kozel; Elke Saile; Chung K Marston; Ann Percival; Brian D Plikaytis; Adrian R Woolfitt; Maribel Gallegos; Patrick Sabourin; Lisa G McWilliams; James L Pirkle; John R Barr
Journal:  Infect Immun       Date:  2009-06-08       Impact factor: 3.441

9.  Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

Authors:  Johnny W Peterson; Scott T Moen; Daniel Healy; Jennifer E Pawlik; Joanna Taormina; Jason Hardcastle; John M Thomas; William S Lawrence; Cindy Ponce; Bagram M Chatuev; Bryan T Gnade; Sheri M Foltz; Stacy L Agar; Jian Sha; Gary R Klimpel; Michelle L Kirtley; Tonyia Eaves-Pyles; Ashok K Chopra
Journal:  Open Microbiol J       Date:  2010-06-03

10.  Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax.

Authors:  Srinivas Kammanadiminti; Ravi Kumar Patnaikuni; Jason Comer; Gabriel Meister; Chris Sinclair; Shantha Kodihalli
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.